trial · primary record
BAY 3401016
Alport Syndrome
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 60 |
| Primary completion | 2027-11-29 |
| Primary endpoint | Urinary albumin creatinine ratio (UACR) ratio to baseline averaged over 16, 20 and 24 weeks of treatment |
| Registry ID | NCT07211685 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:31:48.072Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07211685
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.